35 years of commitment in Hungary

We have been working for 35 years to get Roche's most innovative medicines to the Hungarian patients. Since then, we have contributed to the treatment of the patients with 74 therapies.

Our mission is to close the gap between the Hungarian and European patients’ outcomes by building partnerships with Hungarian patients and the healthcare system’s stakeholders, utilizing Roche’s portfolio and beyond.

Delivering better outcomes for more patients faster

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Combining our strengths in pharmaceuticals and diagnostics, Roche is uniquely positioned to make Personalized Health Care (PHC) a reality. 

 

We have been working for 35 years to get Roche's most innovative medicines to the Hungarian patients.

Due to continuous investment, the pharmaceutical, diagnostics and diabetes business lines as well as the Roche service centre opened in Hungary in 2006 (RSS) have more than 1,000 employees.

 

 

number of employees
nationalities

 

Also located in Budapest is the European Registration Centre, which participates in Roche's administrative tasks in relation to registration procedures and coordinates registration submissions to the EU’s national authorities.

In 2019, the investments in Hungary continued. Roche Hungary has also won the competition for the venue of the European Centre for The Safety of Medicinal Products.

 

These facts show that Roche is an established and important contributor  to the Hungarian economy. We invested almost ¾ (74%) of our domestic revenue back into the country last year. Thus, in 2019 our total contribution to Hungary’s GDP was HUF 20,6 bn, i.e. 0,04% of the total GDP.

 

contribution

 

In the same year, Roche involved 720 Hungarian patients in clinical trials across 117 sites. In total, we conducted 64 research studies across six therapeutic areas such as oncology, immunology/inflammatory disease, neurology/psychiatry, pulmonology, hematology/nephrology, and ophthalmology.

 

Roche Clinical Trials

 

The majority of our trials are still related to  oncology, but we are launching more and more in neurology and ophthalmology as well. Most importantly, Roche made payments totaling to HUF 1,6 bn (CHF 5,6 mio) and saved HUF 4,4 bn (CHF 15,1 mio) for the Hungarian drug budget.

 

statistics

 

Our aim is to ensure that screening, diagnosis, treatment and even prevention of diseases      transform the lives of people more quickly and effectively everywhere – by providing the right treatment for the right patient at the right time.

We believe that to address the big challenges in healthcare we will be required to better integrate, use and share data, and that the advances we have made to offer more personalized and patient-centered care will provide real opportunities to improve patient outcomes and to increase system efficiency.

 

Our mission is to close the gap between the Hungarian and European patients’ outcomes by building partnerships with Hungarian patients and the healthcare system’s stakeholders, utilizing Roche’s portfolio and beyond.

 

 

Data published here are for informative purposes only, they don’t substitute medical check-ups. If you need further information, please turn to your treating physician.